| carbonic acid inhibitor |
<pharmacology> A group of diuretic medications which act to inhibit the enzyme carbonic anhydrase to create a metabolic acidosis. Many of these medications are used in the treatment of glaucoma.
(27 Sep 1997) |
| carbonic anhydrase inhibitor |
<pharmacology> A group of medications (sulphonamide drugs) which inhibit the enzyme carbonic anhydrase. These medications are used in the treatment of glaucoma.
Examples include acetazolamide, dichlorphenamide and methazolamide.
(27 Sep 1997) |
| mammary derived growth inhibitor |
Fatty acid binding protein that inhibits proliferation of mammary carcinoma cells.
(18 Nov 1997) |
| mechanism-based inhibitor |
A competitive inhibitor that is converted to an irreversible inhibitor at the active site of the enzyme.
Synonym: mechanism-based inhibitor.
(05 Mar 2000) |
| glucosidase inhibitor |
Agents such as acarbose which reduce gastrointestinal absorption of carbohydrates. This group of drugs has been known popularly as "starch blockers". They lower plasma glucose levels and tend to cause weight loss. A limiting side effect is flatulence.
(05 Mar 2000) |
| medication, ace-inhibitor |
Agents that inhibit ACE (angiotensin-converting enzyme), thereby acting as vasodilators (really as anti-vasoconstrictors), lightening the stress load on the heart.
(12 Dec 1998) |
| residual inhibitor |
A sound-generating device, worn in the ear, which inhibits or suppresses the sounds of tinnitus by masking, with a residual inhibitory effect when the device is turned off.
(05 Mar 2000) |
| respiratory inhibitor |
A compound that inhibits the respiratory chain.
Synonym: respiratory poison.
(05 Mar 2000) |
| cholinesterase inhibitor |
<pharmacology> These are substances which which act to inhibit acetylcholinesterase, the enzyme which breaks down acetylcholine and thus enhance and subsequently prevent transmission of nerve impulses from one nerve cell to another or to a muscle.
Examples include pyridostigmine, ambenonium and neostigmine.
(15 Jan 1998) |
| monoamine oxidase inhibitor |
<pharmacology> A drug that interferes with the action of monoamine oxidase, slowing the breakdown of certain neurotransmitters. Used in the treatment of depression.
Monoamine oxidase inhibitors are a group of antidepressant drugs that prevent the activity of the enzyme monoamine oxidase in the central nervous system (brain) thus affecting mood. The use of these medications is often restricted due to their severe side effects and drug (and food) interactions.
Examples include isocarboxazid, pargyline, selegiline, furazolidone and phenelzine.
Acronym: MAOI
(26 Mar 1998) |
| complement cytolysis inhibitor |
<protein> Vertebrate glycoprotein of uncertain function. Secreted as a 400 amino acid peptide, then cleaved to form two 200 amino acid peptides that are linked by a disulphide bridge.
Synonym: complement associated protein, complement cytolysis inhibitor, glycoprotein III.
(11 Jan 1998) |
| plasminogen activator inhibitor 1 |
<chemical> A member of the serpin family of proteins. It inhibits both the tissue-type and urokinase-type plasminogen activator.
Pharmacological action: serine proteinase inhibitors.
(12 Dec 1998) |
| plasminogen activator inhibitor 2 |
<chemical> Member of the serpin family of proteins. It inhibits both the tissue-type and urokinase-type plasminogen activator.
Pharmacological action: serine proteinase inhibitors.
(12 Dec 1998) |
| cyclooxygenase inhibitor |
<pharmacology> Compounds or agents that combine with cyclooxygenase (prostaglandin-endoperoxide synthase) and thereby prevent its substrate-enzyme combination with arachidonic acid and the formation of eicosanoids, prostaglandins, and thromboxanes.
(08 Mar 2000) |
| protease inhibitor |
A drug that binds to and blocks HIV protease from working, thus preventing the production of new infectious viral articles.
(09 Oct 1997) |
